

#4

**PATENT**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Lyndell E. Kelly

**Examiner:** Unassigned

**Serial No.:** 10/069,914

**Art Unit:** Unassigned

**Filed:** February 28, 2002

**Docket:** 15317

**For:** TREATMENT OF PANCREATIC  
DISEASE

**Dated:** July 18, 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**  
**AUG - 1 2002**  
TECHNOLOGY CENTER R3700

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following reference(s), which is (are) also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Bhatia, M., et al., "Induction of Apoptosis in Pancreatic Acinar Cells Reduces the Severity of Acute Pancreatitis", Biochemical and Biophysical Research Communications 246: 475-483 (1998);
2. Maher, M., et al., "The Acute Pancreatotoxic Effects of the Plant Nitrile 1-Cyano-2-hydroxy-3-butene", Pancreas 6(2): 168-174 (1991);

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on July 18, 2002.

Dated: July 18, 2002


  
Michelle Mustafa

3. Wallig, M. A., et al., "Selective Pancreatotoxicity In The Rat Induced By The Naturally Occurring Plant Nitrile 1-Cyano-2-Hydroxy-3-Butene", Fd Chem. Toxic, 26(2): 137-142 (1988); and
4. Wallig, M.A., et al., "Enhancement of Pancreatic and Hepatic Glutathione Levels in Rats during Cyanohydroxybutene Intoxication", Fundamental and Applied Toxicology 14: 144-159 (1990).

The references were cited in a Search Report received from the International Searching Authority dated November 6, 2000. Applicant is submitting a copy of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.


Respectfully submitted,

  
Edward W. Grolz  
Registration No. 33,705

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

EWG:ab

3700 3162 0800 07/17/02

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 15317
In Re Application Of: Lyndell E. Kelly			
Serial No. 10/069,914	Filing Date February 28, 2002	Examiner Unassigned	Group Art Unit Unassigned
Title: TREATMENT OF PANCREATIC DISEASE			
<div></div> <div>Address to: Assistant Commissioner for Patents Washington, D.C. 20231</div> <div><b>37 CFR 1.97(b)</b></div> <div>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</div> <div><b>37 CFR 1.97(c)</b></div> <div>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</div> <div><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</div> <div>OR</div> <div><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</div> <div><div>RECEIVED AUG - 1 2002 TECHNOLOGY CENTER R3700</div></div>			

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
15317

In Re Application: Lyndell E. Kelly


Serial No.  
10/069,914

Filing Date  
February 28, 2002

Examiner  
Unassigned

Group Art Unit  
Unassigned

TREATMENT OF PANCREATIC DISEASE



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited July 18, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Michelle Mustafa

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Dated: July 18, 2002

Edward W. Grolz  
Registration No. 33,705  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

RECEIVED  
AUG - 1 2002  
TECHNOLOGY CENTER R3700

cc: